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| INTRODUCTION
Allergic rhinitis with and without asthma affects at least 400 million people worldwide, and the current estimated prevalence is up to 40%.
Pharmacotherapy with antihistamines and nasal corticosteroids can provide symptomatic relief in most but not all patients.
1,2 Allergen immunotherapy (AIT), administered either subcutaneously or sublingually, provides long-term relief of allergy symptoms and is recommended for patients whose seasonal allergies are not effectively controlled by pharmacotherapy. [3] [4] [5] [6] However, patient adherence to AIT is low, and therefore, efficiency is suboptimal because current immunotherapy regime requires frequent treatment over several years. [7] [8] [9] Adjuvant-free allergen peptide hydrolysates ranging 1-10 kDa from Lolium perenne (LPP) for immunotherapy use have been shown to have limited IgE binding, basophil, and mast cell reactivity and hence are considered as a safe alternative that can be administered at higher doses and for a shorter period to improve treatment adherence. 10, 11 Moreover, in a dose-response, double-blind, placebo-controlled study where 198 adults with grass pollen-induced allergic rhinitis received either placebo, 70, 170, or 370 lg, a cumulative dose of 170 lg of LPP over 3 weeks was the optimal dose in terms of surrogate efficacy and benefit/risk balance. 12 In this study, a dose-dependent allergenspecific IgG4 and blocking antibodies were induced.
We sought to investigate the clinical efficacy and safety of a cumulative dose of 170 lg LPP administered subcutaneously over 3 weeks. Here, we present the results of a multicenter, randomized, double-blind, placebo-controlled trial with grass pollen-allergic patients treated in 4 visits over 3 consecutive weeks with LPP. Clinical efficacy was primarily assessed using the combined clinical symptom and medication score (CSMS) as recommended by the European Academy of Allergy and Clinical Immunology (EAACI). 13 In addition, patient QOL reactivity and CPT reactivity to grass pollen allergen were assessed, and adverse events were documented.
| ME TH ODS

| Study design and ethics
This was a randomized, double-blind, placebo-controlled, international and multicenter trial conducted in 57 sites in six countries in to grass pollen mix extract, specific IgE against grass pollen allergens > 0.7 kU/L, a positive CPT to grass pollen allergen (≤10 000 standardized quality units; see Data S1) and have received anti-allergic medications for at least two consecutive grass pollen seasons.
Patients with confirmed diagnosis of grass pollen-induced controlled asthma according to the 2014 Global Initiative for Asthma guidelines were included in the study as well. 15 Patients were excluded if they had received immunotherapy with grass pollen allergens within the preceding 5 years, were currently receiving immunotherapy of any kind, had a history of anaphylaxis, were hypersensitive to the excipients of the investigational product, had a forced expiratory volume in 1 second <80% of the predicted value or a peak expiratory flow <70%, were symptomatic to other inhaled allergens present during the grass pollen season or to perennial inhaled allergens (house dust mites, cat, dog) to which they were regularly exposed, or had a contraindication for epinephrine.
Patients with a history of significant renal disease, chronic hepatic disease, malignant disease, and severe autoimmune disease were excluded.
| LPP and placebo
Lolium perenne pollen peptides is an adjuvant-free mixture of peptides (1-10 kDa) resulting from the enzymatic hydrolysis of L. perenne purified proteins as described in Shamji et al. 11 LPP was M € OSGES ET AL.
| 1843 supplied in ready-to-use vials containing 1.5 mL of 100 lg/mL grass pollen peptides in sterile aqueous-buffered solution (pH 7.4). The placebo was provided in identical ready-to-use vials containing 1.5 mL of sterile aqueous-buffered solution. The vials were numbered with computer-generated randomization codes.
| Study design
Eligible patients were randomized 2:1 to LPP or placebo. Treatments were assigned using a central allocation system. Each treatment consisted of eight subcutaneous injections at 4 visits over 3 consecutive weeks between January and April, 2016. At each treatment visit, the patient received a first injection in one arm, followed 30 minutes later by a second injection in the opposite arm. Doses were increased incrementally starting with 2 9 5 lg at 1st visit, 
| Endpoints
The primary endpoint was the daily CSMS during the peak pollen period, which was calculated as the daily rhinoconjunctivitis total symptom score (RTSS)/6+ rescue medication score (RMS) over the peak of the grass pollen season, as described previously. 13 Secondary efficacy endpoints included individual symptom (NSS, ESS) and medication scores over the peak and entire pollen season, and number of well days. A well day was defined as a day with a RTSS ≤ 2 and no rescue medication needed (RMS = 0). Change in CPT
A total of 554 patients were included and randomized. Of the 182 patients randomized to placebo, 178 started treatment, of which 3 discontinued treatment early, 2 discontinued before the end of the study, and 173 completed the trial. Of the 372 patients randomized to LPP, 367 started treatment, of which 22 discontinued treatment early, 6 discontinued before the end of the study, and 339 completed the trial. ITT population consisted of 171 placebos and 339 LPP-treated patients. AE, adverse event; LPP, Lolium perenne pollen peptides reactivity was assessed before and after treatment and was scored from 0 (unreactive) to 4 (highest) as described previously 17, 18 (see Data S1 for details). Quality of life was evaluated using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) 19 and Noc- 
| Study size estimate
Using a 2:1 randomization ratio and assuming a mean daily CSMS of 1.55 in the placebo group with a standard deviation of 1.0, a sample size of 165 patients in the placebo group and 330 patients in the LPP group is needed to detect a statistically significant (P < .05) difference in mean daily CSMS of 20% between the 2 groups with a power of 90%. 13 To account for a 10% and a 15% dropout rate during the treatment phase and the pollen season, respectively, 654 randomized patients were targeted for corticosteroids.
| Statistical analysis
Statistical analyses were performed using SAS â version 9.4 (SAS Institute, Cary, NC, USA). The primary analysis was the intention-totreat (ITT) using the efficacy assessments from all patients who 
| RESULTS
Five hundred and fifty-four patients were randomized and 512 (92%) completed treatment ( Figure 1 ). Demographics and baseline disease characteristics were similar between the placebo and LPP groups (Table S1 ). The most common cosensitization in both groups was birch pollen, followed by house dust mites, cat epithelia, and 
| Clinical efficacy outcomes
The mean daily CSMS during the peak pollen period was significantly lower in the LPP group than in the placebo group (the primary efficacy assessment), indicating better control of symptoms in the LPP group than in the placebo group (Table 1) . The treatment effect corresponded to a relative mean difference of 15.5% in favor of LPP (P = .041). Similarly, mean daily RTSS, NSS, ESS were also significantly lower in the LPP group compared with placebo (Table 1) , but not for RMS. Patients in the LPP group had more number of well days (+23.0%, P = .044) during the peak pollen period than patients in the placebo group.
When assessed over the entire pollen season, the difference in CSMS was 17.9% in favor of LPP (P = .029; Figure S1 , Table 1 ). (P < .0001) (Figure 2 ). The mean change in CPT score was also significantly larger in the LPP group than in the placebo group (À0.8 AE 0.8 vs À0.4 AE 0.9, P < .001; Table S2 ). In a post hoc analysis, the relationship between CPT reactivity at baseline and the CSMS during the peak pollen period and entire pollen season was assessed. Both the mean CSMS in the placebo group and the difference in mean CSMS between the placebo and LPP group, increased when the CPT reactivity at baseline was higher (Table S3) . When looking at the most CPT reactive patients, that is, those with a baseline CPT score of 3 or 4 (representing 57.9% the patients, Table S3 ), the mean relative difference of CSMS was À19.8% (P = .051) over the peak period and À24.4% (P = .047) over the entire pollen season ( Figure 3A -B and Table S4 ).
| Quality of life assessments
Whereas overall RQLQ and NRQLQ scores were similar in both groups prior to the pollen season, patients in the LPP group reported a better rhinoconjunctivitis-related QOL during the pollen season than those in the placebo group (Table 2) . A significant treatment effect was observed at V7 (À17.1%; P = .005) with the overall RQLQ assessment. Similarly, overall NRQLQ score was significantly lower in the LPP group at the visit performed during the grass pollen season. Also in most RQLQ and NRQLQ subdomains, mean scores were significantly lower in the LPP group compared with placebo. In a post hoc analysis, the treatment effect on QOL in patients with highest CPT reactivity at baseline was found to reach 29.2% for RQLQ and 20.7% for NRQLQ (Table S5 ).
| Safety outcomes
Early systemic reactions (ESR, ie, within 30 minutes of treatment)
were reported in 10.1% of patients (37/368) in the LPP group and were mild (99 for LPP, 7 for placebo). The remainder were moderate (12 for LPP, 1 for placebo). In all cases, the event resolved without medical assistance, and none was considered as serious.
No wheal diameter exceeded 5 cm, 30 minutes after injection, and so no dose adjustment was required per protocol. Nineteen patients (5.2%) discontinued the study treatment due to a TEAE considered as related to LPP (some of which continued in the study), the main cause being a SR.
| DISCUSSION
For the first time, we report the clinical efficacy and safety of a 3-week treatment administered subcutaneously over 4 visits prior the grass pollen season with an adjuvant-free Lollium perenne peptides (LPP) ranging 1-10 kDa. CSMS was reduced in LPP-treated group compared with placebo. Furthermore, LPP treatment was well tolerated as the majority of the patients reached accumulative dose of 170 lg.
The primary outcome measure was the assessment of the daily CSMS during the peak pollen season. In this study, we showed a significantly lower mean CSMS over the peak pollen season of 15% for LPP vs placebo. The low magnitude in the reduction may have been due to a relatively mild grass pollen allergy season, as indicated by relatively low symptom scores (mean RTSS <4.5 out of a maximum of 18 during peak and <3.2 over the entire season) and low rescue medication use in the placebo arm: The mean RMS in the placebo group during both the pollen peak (0.698) and the full pollen season (0.577) indicated that, on average, only 2 of 3 patients used any rescue medications daily. It is well known that the magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on the natural pollen exposure. 22, 23 Consistent with these findings, post hoc analysis showed that the difference in CSMS during the pollen peak was about 20% when limited to patients with more severe grass pollen sensitivity at baseline (representing 57.9%
of the whole study population) and 24.4% over the entire pollen season.
Short-course immunotherapy approach with whole allergen extract has been used in grass pollen-induced allergic rhinitis. One study showed a 26.6% decrease in median combined score during the first year and a 48.4% decrease the second year in grass pollenallergic adults who received weekly subcutaneous of alum-adsorbed six-grass pollen extract just before each pollen season. 24 A decrease of 12.7% during the entire grass pollen season and 13.6% during the pollen peak was reported in patients who received four preseason subcutaneous injections of monophosphoryl lipid A-adjuvanted tyrosine-adsorbed 13-grass pollen extract. 25 A decrease of 15.6% the first year and 33% the second year was reported in patients who each year received five preseason subcutaneous injections of alumadsorbed depigmented grass pollen extract. 26 Although comparison of results of different studies has to be performed with caution because scores, statistical methods, study designs, pollen seasons, and regions may be different, the 15.5%-24.4% improvement in CSMS observed after LPP treatment appeared to be within the range reported for other short-term grass pollen immunotherapies with adjuvanted products.
The effect of LPP appeared to be more pronounced on the changes in allergic symptoms (mean RTSS, NSS, and ESS were significantly lower with LPP than with placebo), than on rescue medication. In agreement with this, patients receiving LPP also had more well days, a lower impairment of quality of life in season (diurnal and nocturnal) and a greater decrease in grass pollen CPT scores than patients receiving placebo.
Injections with whole pollen antigens can cause severe systemic reactions, so injections must be performed under medical supervision where resuscitation equipment is available, and patients need to be monitored for 30-60 minutes after injections. 27 At the same doses, LPP are less likely than the whole grass pollen allergen protein to cross-link high-affinity IgE receptors and cause allergic reactions, Included one serious event of conjunctival injection, throat clearing, and urticaria, followed by abdominal cramps, retrosternal pain, dyspnea, nausea, and extension of the urticaria. Included one serious event of tightness of the chest, followed by dizziness and decreased blood pressure.
although LPP is administered at higher dose to allow for the shortcourse treatment regimen. 11 Three patients (<1%) treated with LPP Although a different grading system was used than the current study, the data of this study suggest that LPP was overall well tolerated, in agreement with the concept of peptide immunotherapy. 10 Importantly, 89% reached the full dose of 170 lg LPP in the planned eight injections (four treatment visits of two injections) and another 5% reached the full dose after a dose adjustment.
A limitation of this study was an unexpectedly high number of screening failures, which was mainly due to the exclusion of patients in whom birch pollen allergy was dominant. Despite this, the population was large enough to detect clinically and statistically significant improvements in allergic rhinitis symptoms as well as relevant safety data. The modest CSMS treatment effect observed may also be due to the inclusion of patients with limited allergy severity, as suggested by the increased treatment effect observed in patients with highest CPT reactivity at baseline. Another apparent limitation is the number of missing data, especially outside the peak pollen period, which is due to noncompliance of patients with the requirement of scoring symptoms and medication on a daily basis for several weeks, even in the absence of symptoms. Considering that all efficacy data show similar results, including the QOL scores for which only a limited number of data were available, these missing data are not considered to impact significantly on efficacy data and conclusions.
In conclusion, this study showed that a short-course treatment with LPP over 3 weeks just before the pollen season was effective and limited CSMS in patients with seasonal allergic rhinitis with and without asthma. LPP offers the possibility of a much shorter treatment course and therefore better compliance and efficiency than standard SCIT using conventional whole allergen extracts. LPP treatment was safe and well tolerated. However, as with conventional SCIT, patients should be monitored for adverse reactions, and dose adjustment should be made if necessary.
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